TAG1 Inc., a radioisotope company specializing in high-purity Lead-212 production, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025. The conference, hosted at The Venetian Resort, will bring together innovative companies and institutional investors for strategic discussions and networking opportunities.
CEO Sumit Verma will be a key participant, speaking on a panel titled "Radiopharma Isotope Roadmap: Clinical & Logistical Considerations." The panel, scheduled for April 9 at 9:00 AM, will feature executives from Lantheus Holdings and Radiopharm Theranostics, and will be moderated by JonesTrading's Justin Walsh.
The conference represents a significant opportunity for TAG1 to showcase its progress in strengthening the global supply chain for Targeted Alpha Therapies (TATs). By providing high-purity Lead-212, the company is addressing critical needs in cancer treatment research and development.
In addition to the panel discussion, TAG1 will deliver a virtual company presentation on April 9 at 3:00 PM and participate in one-on-one investor meetings. These interactions will allow the company to communicate its strategic vision and technological innovations directly to potential investors and industry partners.
The event underscores the growing importance of specialized radioisotopes in advancing precision cancer treatments. By focusing on Lead-212 production, TAG1 is positioning itself at the forefront of a potentially transformative approach to targeted cancer therapies.
